Digitoxin: A Natural Digoxin Alternative
- What: The FDA approved Arexvy,a respiratory syncytial virus (RSV) vaccine,for adults aged 60 years and older.
- When: Approved May 3, 2023, wiht updated recommendations in September 2025.
- Why it matters: RSV causes significant illness and hospitalization in older adults, and this is the first widely available vaccine to prevent it.
RSV Vaccine Approved for Older Adults: A Breakthrough in Respiratory Protection
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization.Prior to the advancement of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the United States. The virus weakens the respiratory system, making individuals more vulnerable to secondary infections.
The impact of RSV is often underestimated. Symptoms can mimic influenza or COVID-19, leading to delayed diagnosis and treatment. Furthermore, the long-term effects of RSV infection, such as decreased functional capacity and increased risk of chronic respiratory conditions, are becoming increasingly recognized.
the Arexvy Vaccine: How It Works
Arexvy, developed by GSK, is a recombinant subunit vaccine. this means it doesn’t use a live virus. Instead, it contains a stabilized prefusion F protein, a key component of the RSV virus that triggers an immune response. The vaccine works by prompting the body to create antibodies that recognize and neutralize the virus, preventing infection or reducing the severity of illness.
Clinical trials,as published in the New England Journal of Medicine, Volume 393, Issue 12 (September 25, 2025), demonstrated approximately 82.6% efficacy in preventing RSV-associated lower respiratory tract disease (LRTD) in adults 60 years and older. The trials also showed a significant reduction in severe RSV-associated disease.
Key Findings from the Clinical Trials
| outcome | Arexvy Group | Placebo Group | efficacy |
|---|---|---|---|
| RSV-associated LRTD | 1.4% | 8.0% | 82.6% |
| Severe RSV-associated disease | 0.4% | 2.1% | 81.5% |
It’s vital to note that, as with any vaccine, Arexvy isn’t 100% effective. Though, the substantial reduction in both LRTD and severe disease represents a significant advancement in protecting older adults from the potentially devastating effects of RSV.
Who Should get the RSV Vaccine?
The Centers for Disease Control and Prevention (CDC) recommends that adults aged 60 years and older may receive a single dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider. this means a discussion about individual risk factors, potential benefits, and any contraindications.
Factors to consider include:
- Age
- underlying health conditions (e.g., heart disease, lung disease, diabetes)
- Lifestyle